Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.BTX · Entity 8278 | Chief Administration Officer | March 11, 2022 | March 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date March 11, 2022 · Filed March 18, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2032-03-11 | Direct | 117,200 |
Reported balance
After 2022-03-11 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-03-11 · Grant · Acquired 117,200 · Balance 117,200 F1: The options vest and become exercisable in 36 substantially equal monthly installments from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable in 36 substantially equal monthly installments from the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2022 Filed Mar 16, 2022 01:34 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 117,200 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009661 · form4.xml · derivative · entry 1 Sial Jay · CIK 0001873057 · Chief Administration Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,200 Underlying: Common Stock · 117,200 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable over three years, with 25% of the options vesting on the one-year anniversary of the grant date and the remaining options vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 11, 2022 Filed Mar 18, 2022 01:00 UTC Amendment | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 117,200 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009981 · form4.xml · derivative · entry 1 Sial Jay · CIK 0001873057 · Chief Administration Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,200 Underlying: Common Stock · 117,200 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable in 36 substantially equal monthly installments from the grant date. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 01:30 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantRestricted Stock Unit · Derivative | 35,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-024855 · form4.xml · derivative · entry 2 Sial Jay · CIK 0001873057 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,700 Underlying: Common Stock · 35,700 shares Expires 2031-07-15 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The RSU Grant vests and becomes exercisable in four equal installments on July 15 of each of 2022, 2023, 2024 and 2025, provided that it shall vest in full immediately prior to a change in control (as defined in Mr. Sial's Executive Employment Agreement, dated as of July 6, 2021 and effective July 15, 2021), subject to continued service through each vesting date. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 01:30 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option · Derivative | 71,000 | $0.00 Strike: $10.31 | $0.00 |
DisclosureSEC source: 0001140361-21-024855 · form4.xml · derivative · entry 1 Sial Jay · CIK 0001873057 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2031-07-15 F1 · derivative.exercise_date: The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on July 15, 2022, and 1/36 of the remaining shares covered thereby vesting on the 15th day of each calendar month from August 2022 through July 15, 2025, subject to continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.